InsidersTradesSigma
Track the Adlai Nortye Group Ltd. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €913.8m. The latest transaction was filed on 26 August 2026 (Cession). Among the most active insiders: Ye Xiaofeng. Every trade is free.
Analysts rate Adlai Nortye Group Ltd. Strong Buy (bullish), based on 5 analysts. Average price target: US$28.60.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Adlai Nortye Group Ltd. is a biopharmaceutical company focused on developing innovative treatments for cancer. It is listed on NASDAQ under the ticker ANTE.